Biomarkers of Alzheimer’s Disease

Posted on February 24th, 2017

Early detection of Alzheimer’s Disease is paramount to beginning early treatment. Early treatment – prior to high levels of amyloid beta tangles and permanent brain damage has a much higher chance of success.

This article is the most comprehensive online listing of the biomarkers of Alzheimer’s Disease compiled by anyone so far. Contact us if you would like to suggest a biomarker or know of a more comprehensive list.

Traditional markers of Alzheimer’s include tau proteins, amyloid precursor proteins and amyloid beta levels in cerebral spinal fluid (CSF). These markers are useful indicators of the progression of neurodegeneration in Alzheimer’s Disease. However, they are later stage markers that indicate the disease is in full force.

Amyloid Precursor Protein to Amyloid Beta Cascade

A decrease in hematopoetic stem cells that give rise to all the other blood cells through the process of haematopoiesis [W] and a decrease in neurotrophic factors have been shown to have negative consequences for repair of existing neurons. Neurotrophic factors are proteins and peptides that support the growth, survival, and differentiation of both developing and mature neurons – without which the brain is no longer able to repair itself or grow. Additionally, evidence of blockage of CSF circulation caused by whiplash and other traumatic neck injuries may result in reduced clearance of amyloid beta by immune cells. This CSF blockage may have early diagnostic potential in a new form of MRI test, called Upright MRI. [R]

Other major risk factors include midlife high blood pressure, diabetes, and APOE4 genetics. See below for a full list.

Early Indicators of Alzheimer’s Disease

Very Early Indicators of Alzheimer’s Disease Risk
(Less than 50 Years Old)

Genetic Risk Factors of Alzheimer’s Disease

Genetic Risk Factors for Alzheimer's Disease

Genetic Risk Factors for Alzheimer’s Disease

Early Onset and Familial Alzheimer’s Disease

The early onset of Alzheimer’s is usually driven by extreme factors. Severe physical trauma to the brain like multiple concussions or a high level of toxicity is a good example. Another example, not to be forgotten, is severe emotional trauma. Post traumatic stress disorder symptoms appear identical to Alzheimer’s Disease in clinical presentation (what a patients acts, looks and feels like). Genetics often plays a part in accelerating early onset Alzheimer’s.

Purely genetics triggered Alzheimer’s Disease (without major trauma to the brain) is actually a different disease altogether called Familial Alzheimer’s Disease (FAD) and is quite rare. It is not something you need to worry about getting if your family does not have a history of early onset Alzheimer’s Disease. This is not an area of focus for Soldara research.  If you would like to learn more about it, a good place to start is the National Institute on Aging. FAD is driven by three known genes:

Late Onset Alzheimer’s Disease (LOAD)

Late onset Alzheimer’s Disease is not triggered by genetics. Genetics merely increase your risk. Knowing your genetics can can give you the information you need to build a healthy lifestyle personalized to your genetics.


  1. Avagyan, Hripsime, et al. “Immune blood biomarkers of Alzheimer disease patients.” Journal of neuroimmunology 210.1 (2009): 67-72. [R]
  2. Laske, Christoph, et al. “Decreased brain-derived neurotrophic factor (BDNF)-and beta-thromboglobulin (beta-TG)-blood levels in Alzheimer’s disease.” THROMBOSIS AND HAEMOSTASIS-STUTTGART- 96.1 (2006): 102. [R]
  3. Laske, Christoph, et al. “Decreased CXCL12 (SDF-1) plasma levels in early Alzheimer’s disease: a contribution to a deficient hematopoietic brain support?.” Journal of Alzheimer’s Disease 15.1 (2008): 83-95. [R]
  4. Laske, Christoph, et al. “Decreased plasma and cerebrospinal fluid levels of stem cell factor in patients with early Alzheimer’s disease.” Journal of Alzheimer’s Disease 15.3 (2008): 451-460. [R]
  5. Gardener, Samantha L., et al. “Cerebral glucose metabolism is associated with verbal but not visual memory performance in community-dwelling older adults.” Journal of Alzheimer’s Disease 52.2 (2016): 661-672. [R]
  6. Swan, Gary E., et al. “Association of midlife blood pressure to late-life cognitive decline and brain morphology.” Neurology 51.4 (1998): 986-993. [R]
  7. Small, Brent J., et al. “Apolipoprotein E and cognitive performance: a meta-analysis.” (2004): 592. [R]
  8. Stewart, R., and D. Liolitsa. “Type 2 diabetes mellitus, cognitive impairment and dementia.” Diabetic Medicine 16.2 (1999): 93-112. [R]
  9. Itzhaki, R. F., et al. “Infiltration of the brain by pathogens causes Alzheimer’s disease.” Neurobiology of aging 25.5 (2004): 619-627. [R]
  10. Steiner, Israel, Peter GE Kennedy, and Andrew R. Pachner. “The neurotropic herpes viruses: herpes simplex and varicella-zoster.” The Lancet Neurology 6.11 (2007): 1015-1028. [R]
  11. Itzhaki, R. F., et al. “Infiltration of the brain by pathogens causes Alzheimer’s disease.” Neurobiology of aging 25.5 (2004): 619-627. [R]
  12. Mahley, Robert W., and Stanley C. Rall Jr. “Apolipoprotein E: far more than a lipid transport protein.” Annual review of genomics and human genetics 1.1 (2000): 507-537. [R]
  13. Polidori, M. Cristina, et al. “Plasma antioxidant status, immunoglobulin g oxidation and lipid peroxidation in demented patients: relevance to Alzheimer disease and vascular dementia.” Dementia and geriatric cognitive disorders 18.3-4 (2004): 265-270. [R]
  14. Tosto, Giuseppe, and Christiane Reitz. “Genome-wide association studies in Alzheimer’s disease: a review.” Current neurology and neuroscience reports 13.10 (2013): 381. [R]
  15. Naj, Adam C., et al. “Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer’s disease.” Nature genetics 43.5 (2011): 436-441. [R]
  16. Hollingworth, Paul, et al. “Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease.” Nature genetics 43.5 (2011): 429-435. [R]
  17. Zhang, Can, et al. “Loss of function of ATXN1 increases amyloid β-protein levels by potentiating β-secretase processing of β-amyloid precursor protein.” Journal of Biological Chemistry 285.12 (2010): 8515-8526. [R]
  18. Flanagan, Michael F. “The role of the craniocervical junction in craniospinal hydrodynamics and neurodegenerative conditions.” Neurology research international 2015 (2015). [R]
  19. Mullins, Roger J., et al. “Exosomal biomarkers of brain insulin resistance associated with regional atrophy in Alzheimer’s disease.” Human Brain Mapping (2017). [R]
  20. Cruchaga, Carlos, et al. “Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer’s disease families.” PloS one 7.2 (2012): e31039. [R]
  21. Zetterberg, Henrik, et al. “Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease.” Archives of neurology 65.8 (2008): 1102-1107. [R]